Literature DB >> 6459838

Human parathyroid hormone 1-34-mediated hypercalcemia in a rat model, and its inhibition by dichloromethane diphosphonate.

S H Doppelt, R M Neer, J T Potts.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6459838     DOI： 10.1007/bf02409503

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


× No keyword cloud information.
  14 in total

1.  RENAL ADENOCARCINOMA CONTAINING A PARATHYROID HORMONE-LIKE SUBSTANCE AND ASSOCIATED WITH MARKED HYPERCALCEMIA.

Authors:  M F GOLDBERG; A H TASHJIAN; S E ORDER; G J DAMMIN
Journal:  Am J Med       Date:  1964-05       Impact factor: 4.965

2.  Hypercalcemia in neoplastic disease.

Authors:  W P MYERS
Journal:  Arch Surg       Date:  1960-02

3.  Parathyroid hormone and renal handling of Pi: effect of dietary Pi and diphosphonates.

Authors:  J P Bonjour; U Troehler; C Preston; H Fleisch
Journal:  Am J Physiol       Date:  1978-06

Review 4.  Medical management of the hypercalcemia of malignancy.

Authors:  L J Deftos; R Neer
Journal:  Annu Rev Med       Date:  1974       Impact factor: 13.739

5.  Effect of diphosphonates and calcitonin on the chemistry and quantitative histology of rat bone.

Authors:  R G Russell; A M Kislig; P A Casey; H Fleisch; J Thornton; R Schenk; D A Williams
Journal:  Calcif Tissue Res       Date:  1973-03-12

6.  Partial purification of osteoclast-activating factor from phytohemagglutinin-stimulated human leukocytes.

Authors:  R A Luben; G R Mundy; C L Trummel; L G Raisz
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

7.  Relation between bone mineralization, Ca absorption, and plasma Ca in phosphonate-treated rats.

Authors:  U Trechsel; R Schenk; J P Bonjour; R G Russell; H Fleisch
Journal:  Am J Physiol       Date:  1977-03

8.  Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma.

Authors:  E S Siris; W H Sherman; D C Baquiran; J P Schlatterer; E F Osserman; R E Canfield
Journal:  N Engl J Med       Date:  1980-02-07       Impact factor: 91.245

9.  Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

10.  Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo.

Authors:  H Fleisch; R G Russell; M D Francis
Journal:  Science       Date:  1969-09-19       Impact factor: 47.728
View more
  6 in total

Review 1.  Clodronate: a review of its use in breast cancer.

Authors:  M Hurst; S Noble
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

2.  Inhibition of bone mineral loss during lactation by Cl2MBP.

Authors:  R Brommage; D C Baxter
Journal:  Calcif Tissue Int       Date:  1990-09       Impact factor: 4.333

3.  Inhibition of the in vivo parathyroid hormone-mediated calcemic response in rats by a synthetic hormone antagonist.

Authors:  S H Doppelt; R M Neer; S R Nussbaum; P Federico; J T Potts; M Rosenblatt
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

4.  Inhibition by aminohydroxypropylidene bisphosphonate (AHPrBP) of 1,25(OH)2 vitamin D3-induced stimulated bone turnover in the mouse.

Authors:  P J Marie; M Hott; M T Garba
Journal:  Calcif Tissue Int       Date:  1985-05       Impact factor: 4.333

5.  Gut-mediated hypercalcemia in rabbits bearing VX2 carcinoma: new mechanism for tumor-induced hypercalcemia.

Authors:  S H Doppelt; D M Slovik; R M Neer; J Nolan; R M Zusman; J T Potts
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

Review 6.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.